SMTN Targets: A Promising Area of Cancer Research (G6525)

Target Name: SMTN

NCBI ID: G6525

SMTN

SMTN Targets: A Promising Area of Cancer Research

Synthetic Medicine targets (SMTN) are small molecules that are designed to interact with specific proteins and help treat a variety of diseases. One potential SMTN that is currently being targeted for drug development is Smoothelin (ISOform B).

Smoothelin is a protein that is expressed in many different tissues throughout the body, including the brain, heart, and kidneys. It is involved in a variety of physiological processes, including blood clotting and cell signaling. Smoothelin has also been shown to play a role in the development and progression of certain diseases, including cancer.

One of the reasons that Smoothelin makes an attractive drug target is its unique structure. Smoothelin is a member of a family of proteins called serpins, which are known for their ability to regulate water and ion channels in cells. Unlike other proteins that are known for drug targeting, such as toxins or viruses, Smoothelin has a highly conserved, amino acid sequence that makes it difficult to predict the exact structure of its drug binding sites.

This lack of knowledge about the structure of Smoothelin's binding sites has not hindered the development of SMTNs as potential drugs. Researchers have been able to identify a number of potential binding sites on the protein using computer modeling and other techniques. These sites are then used to design small molecules that can interact with Smoothelin and inhibit its activity.

One of the most promising SMTNs that is currently being targeted for drug development is a compound called SML-380. This compound is designed to bind to a specific Smoothelin binding site on the protein and has been shown to inhibit the activity of the protein in cell experiments. SML-380 has also been shown to be effective in animal models of cancer treatment, including in the treatment of mouse models of breast cancer.

Another promising SMTN that is being targeted for drug development is called SMT-225. This compound is designed to bind to a different Smoothelin binding site on the protein and has been shown to inhibit the activity of the protein in cell experiments. SMT-225 has has also been shown to be effective in animal models of cancer treatment, including in the treatment of mouse models of lung cancer.

While the development of SMTNs as potential drugs is an exciting area of 鈥嬧?媟esearch, there are also concerns about the potential side effects of these compounds. For example, some researchers have suggested that SML-380 and SMT-225 may have unintended consequences in the body , such as interacting with other proteins or organs. It will be important for researchers to carefully study these concerns and determine the safety and effectiveness of these SMTNs as drugs.

Overall, Smoothelin (ISOform B) is an attractive drug target due to its unique structure and the promising results of early SMTN studies. While more research is needed to fully understand the safety and effectiveness of these SMTNs as drugs, they are a promising area of research that could lead to new and effective treatments for a variety of diseases.

Protein Name: Smoothelin

Functions: Structural protein of the cytoskeleton

The "SMTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets